A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose

NCT04973111 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes

Interventions

DRUG: CT-868 as SC Injection
DRUG: Placebo as SC Injection
DRUG: Active Comparator as SC Injection

Sponsor

Carmot Therapeutics, Inc.